Skip to main content

Table 3 Main toxicity in 258 patients according to cTcAE version 4.03

From: Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study

Grade 3–4 toxicities; n (%)

Anemia

4 (1.6)

Neutropenia

54 (20.9)

Thrombocytopenia

1 (0.4)

Liver dysfunction

2 (0.8)

Peripheral neuropathy

10 (3.9)

Febrile neutropenia

13 (5.0)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us